Author(s): Kriplani A, Kulshrestha V, Agarwal N
Abstract Share this page
Abstract OBJECTIVE: To assess the efficacy and safety of ormeloxifene (centchroman) in the medical management of menorrhagia. METHODS: Forty-two women with menorrhagia were recruited for the study. Ormeloxifene was given to each patient 60 mg twice a week for 3 months and then once a week for 1 month. Patients were followed up at 2 and 4 months of therapy, then at 3 and 6 months after treatment was stopped. Menstrual blood loss (MBL) was measured objectively by a pictorial blood loss assessment chart (PBAC) score and subjectively by a visual analog scale (VAS). RESULTS: The pretreatment median PBAC score was 388 (range 169-835). Eighteen patients (42.9\%) had amenorrhea with the therapy. Median PBAC reduced to 80 (range 0-730) and 5 (range 0-310) at 2 and 4 months, respectively (P-value <0.001); thus, the percentage reduction was 97.7\% at 4 months. Seven patients (16.7\%) had no response and three (7.1\%) discontinued treatment before 4 months. During the 10-month study period, 21\% of the patients underwent hysterectomy. Adverse effects included ovarian cyst (7.1\%), cervical erosion and discharge (7.1\%), gastric dyspepsia (4.8\%), vague abdominal pain (4.8\%) and headache (4.8\%). CONCLUSION: Ormeloxifene is an effective and safe therapeutic option for the medical management of menorrhagia.
This article was published in J Obstet Gynaecol Res
and referenced in Biochemistry & Physiology: Open Access